Race Oncology (ASX:RAC) has announced a significant expansion of its clinical development strategy, unveiling two new programs for its lead asset, RC220, in acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer.

Syntara (ASX:SNT) has achieved a significant regulatory milestone, announcing it has received a positive opinion from the European Medicines Agency on its application for Orphan Drug Designation for amsulostat (SNT-5505) in myelofibrosis.

Argent BioPharma (ASX:RGT) has taken a significant step toward its next phase of growth, securing a new $11 million financing facility from US-based venture fund C/M Capital to complete the acquisition of AusCann Group assets and accelerate commercial development plans.

Recce Pharmaceuticals (ASX:RCE) has announced the passing of its founder, Dr Graham JH Melrose, a distinguished scientist, inventor and long-time champion of innovative anti-infective technologies.

PYC Therapeutics (ASX:PYC) has reported encouraging long-term data from its ongoing Phase 1/2 clinical program for VP-001, an investigational treatment targeting Retinitis Pigmentosa type 11.

Biotron (ASX:BIT) has released new data demonstrating significant progress in its Hepatitis B Virus development program, with its lead candidate BIT-HBV001 showing potent antiviral effects across multiple laboratory and animal models.

Noxopharm (ASX:NOX) has reached a new milestone in its development of SOF-SKN, announcing that the first dose has now been administered in Part Two of the HERACLES clinical trial.

Pathkey.AI (ASX:PKY) has announced a new partnership with Melbourne-based consultancy Armstrong Clinical, combining advanced artificial intelligence with deep human expertise in clinical development strategy to help sponsors design smarter, more successful early-phase studies.

Australian biotech company RAGE Biotech has raised $29 million in Series A funding to accelerate its lead precision RNA therapy into clinical development, while announcing two senior leadership appointments as it prepares for a pivotal year of growth.

Radiopharm Theranostics (ASX: RAD) has announced that patient enrollment has commenced for the third cohort of its ongoing Phase 1 dose-escalation trial evaluating 177Lu-RAD204, a radiolabeled single-domain antibody targeting PD-L1 in advanced solid tumours.

Arovella Therapeutics (ASX:ALA) has strengthened its Board with the appointment of Dr Andrew Nash, the former Chief Scientific Officer of CSL, as a Non-Executive Director, effective 12 November 2025.

Chimeric Therapeutics (ASX:CHM) has reported encouraging new data from its ongoing Phase 1/2 clinical trial of CHM CDH17, a next-generation CAR-T therapy targeting gastrointestinal cancers.

Nanosonics has appointed William Haydon as Regional President, North America, as the infection prevention company prepares to accelerate commercial expansion and launch its next-generation CORIS platform for endoscope reprocessing.

Cyclopharm (ASX:CYC) has confirmed completion of the sale of its non-core cyclotron asset, receiving $6.2 million in proceeds as part of a broader strategy to sharpen its focus on the company’s global Technegas business.

Microba Life Sciences (ASX:MAP) has announced a series of planned Board changes as part of its renewal process, strengthening governance and commercial capability as the company accelerates its global microbiome business.

AusBiotech is continuing to lift the voices of our members and strengthen and unify the voice of our sector. Having recently refreshed our State Committees we are now refreshing our Advisory Group structures to amplify member voice and harness industry expertise.

Engineers at Monash University are developing a breakthrough heart pump designed specifically for patients with heart failure with preserved ejection fraction. The condition affects half of all people living with heart failure, but no mechanical treatment currently exists.

AVITA Medical (ASX:AVH) has reported third-quarter 2025 results showing improved cash efficiency and progress on several strategic and regulatory milestones.

Australian biotechnology company NeuroScientific Biopharmaceuticals (ASX:NSB) has reached another milestone in its clinical development program, with the commencement of treatment under the Special Access Scheme for its patented StemSmart mesenchymal stem cell therapy in a fourth patient.